These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 560793)

  • 1. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 2. Behavioral implications of dopaminergic neurons in the mesolimbic system.
    Iversen SD; Koob GF
    Adv Biochem Psychopharmacol; 1977; 16():209-14. PubMed ID: 560790
    [No Abstract]   [Full Text] [Related]  

  • 3. Indirect evidence for a feedback loop mechanism between two central dopaminergic pathways: preliminary results.
    Yehuda S
    Commun Psychopharmacol; 1979; 3(2):115-9. PubMed ID: 467002
    [No Abstract]   [Full Text] [Related]  

  • 4. [Stereotyped behavior and the nigro-strio-nigral system].
    Arushanian EB
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1985; 35(5):819-32. PubMed ID: 2866641
    [No Abstract]   [Full Text] [Related]  

  • 5. D-Amphetamine-induced inhibition of central dopaminergic neurons: direct effect or mediated by a striatonigral feedback pathway?
    Bunney BS; Aghajanian GK
    Adv Biochem Psychopharmacol; 1977; 16():577-82. PubMed ID: 883560
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antipsychotic drug modification of motor hyperactivity and stereotyped behavior induced by amphetamine in rats with lesions in the nigrostriatal and mesolymbic dopaminergic systems].
    Sánchez-Blázquez P; Fernández-Tomé MP; Fuentes JA; del Río J
    Arch Farmacol Toxicol; 1978 Apr; 4(1):66-8. PubMed ID: 29574
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitory mechanisms in the substantia nigra and the dopamine pathway.
    Straughan DW; James TA
    Int J Neurol; 1979; 13(1-4):81-93. PubMed ID: 122391
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo electrochemical and behavioral evidence for specific neural substrates modulated differentially by enkephalin in rat stimulant stereotypy and locomotion.
    Broderick PA; Gardner EL; van Praag HM
    Biol Psychiatry; 1984 Jan; 19(1):45-54. PubMed ID: 6538442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic involvement in hypothalamic function: extrahypothalamic and hypothalamic control. A neuroanatomical analysis.
    Fuxe K; Goldstein M; Hökfelt T; Jonsson G; Lidbrink P
    Adv Neurol; 1974; 5():405-19. PubMed ID: 4374065
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dopamine metabolism and the GABA level in the structures of the nigrostriatal and mesolimbic systems of the rat brain in experimental pathology of higher nervous activity].
    Saul'skaia NB
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1988; 38(6):1145-51. PubMed ID: 3245325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between GABA, dopamine, acetylcholine, and glutamate-containing neurons in the extrapyramidal and limbic systems.
    Bartholini G; Scatton B; Worms P; Zivkovic B; Lloyd KG
    Adv Biochem Psychopharmacol; 1981; 30():119-28. PubMed ID: 6120626
    [No Abstract]   [Full Text] [Related]  

  • 12. Lesions of the superior colliculus in the rat differentiate between nigrostriatal and mesolimbic dopamine systems.
    Dawbarn D; Pycock CJ
    Brain Res; 1982 Mar; 235(1):148-55. PubMed ID: 6892367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circling behaviour induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway.
    Oberlander C; Euvrard C; Dumont C; Boissier JR
    Eur J Pharmacol; 1979 Dec; 60(2-3):163-70. PubMed ID: 575095
    [No Abstract]   [Full Text] [Related]  

  • 14. [Neurophysiologic and pharmacologic evidence of autoregulationin the nigrostriatal system].
    Arushanian EB; Tolpyshev BA
    Biull Eksp Biol Med; 1981 Feb; 91(2):133-6. PubMed ID: 7194700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
    Koltai MZ; György L
    Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of haloperidol on dopamine turnover in the striatum, olfactory tubercule and median eminence.
    Gudelsky GA; Moore KE
    J Pharmacol Exp Ther; 1977 Jul; 202(1):149-56. PubMed ID: 874811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

  • 18. [Relation between GABAergic and dopaminergic neurons in the basal ganglia].
    Kemel ML; Gauchy C; Girault JA; Besson JM; Glowinski J
    Encephale; 1987 Jul; 13 Spec No():169-71. PubMed ID: 3319524
    [No Abstract]   [Full Text] [Related]  

  • 19. The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions.
    Crossman AR; Sambrook MA
    Brain Res; 1978 Dec; 159(1):211-3. PubMed ID: 569529
    [No Abstract]   [Full Text] [Related]  

  • 20. Dopaminergic neurons in the nigro-striatal and mesolimbic pathways: mediation of specific effects of D-amphetamine.
    Yehuda S; Wurtman RJ
    Eur J Pharmacol; 1975 Feb; 30(2):154-8. PubMed ID: 1168575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.